vs
Coherus Oncology, Inc.（CHRS）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是Coherus Oncology, Inc.的1.1倍（$14.0M vs $12.7M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -295.3%，领先305.1%），Coherus Oncology, Inc.同比增速更快（64.9% vs 10.4%），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs -47.0%）
Coherus Oncology是一家处于商业化阶段的生物制药企业，专注于肿瘤领域药物的研发、生产与商业化，产品包括肿瘤生物类似药、新型靶向免疫肿瘤疗法，主要面向北美市场，致力于提升癌症患者平价创新治疗方案的可及性。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
CHRS vs RVSB — 直观对比
营收规模更大
RVSB
是对方的1.1倍
$12.7M
营收增速更快
CHRS
高出54.5%
10.4%
净利率更高
RVSB
高出305.1%
-295.3%
两年增速更快
RVSB
近两年复合增速
-47.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $12.7M | $14.0M |
| 净利润 | $-37.6M | $1.4M |
| 毛利率 | 68.3% | — |
| 营业利润率 | -359.9% | 12.4% |
| 净利率 | -295.3% | 9.8% |
| 营收同比 | 64.9% | 10.4% |
| 净利润同比 | 25.7% | 11.8% |
| 每股收益（稀释后） | $-0.34 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHRSRVSB
| Q4 25 | $12.7M | $14.0M | ||
| Q3 25 | $11.6M | $13.6M | ||
| Q2 25 | $10.3M | $13.3M | ||
| Q1 25 | — | $12.9M | ||
| Q4 24 | — | $12.7M | ||
| Q3 24 | — | $12.8M | ||
| Q2 24 | $10.3M | $12.2M | ||
| Q1 24 | — | $9.0M |
净利润CHRSRVSB
| Q4 25 | $-37.6M | $1.4M | ||
| Q3 25 | $-35.5M | $1.1M | ||
| Q2 25 | $297.8M | $1.2M | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | $-12.9M | $966.0K | ||
| Q1 24 | — | $-3.0M |
毛利率CHRSRVSB
| Q4 25 | 68.3% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 66.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 82.4% | — | ||
| Q1 24 | — | — |
营业利润率CHRSRVSB
| Q4 25 | -359.9% | 12.4% | ||
| Q3 25 | -383.1% | 10.2% | ||
| Q2 25 | -443.6% | 11.7% | ||
| Q1 25 | — | 11.3% | ||
| Q4 24 | — | 12.4% | ||
| Q3 24 | — | 15.5% | ||
| Q2 24 | -384.9% | 10.0% | ||
| Q1 24 | — | -47.5% |
净利率CHRSRVSB
| Q4 25 | -295.3% | 9.8% | ||
| Q3 25 | -307.1% | 8.1% | ||
| Q2 25 | 2903.9% | 9.2% | ||
| Q1 25 | — | 8.9% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | — | 12.2% | ||
| Q2 24 | -125.5% | 7.9% | ||
| Q1 24 | — | -34.7% |
每股收益（稀释后）CHRSRVSB
| Q4 25 | $-0.34 | $0.07 | ||
| Q3 25 | $-0.31 | $0.05 | ||
| Q2 25 | $2.57 | $0.06 | ||
| Q1 25 | — | $0.05 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | — | $0.07 | ||
| Q2 24 | $-0.11 | $0.05 | ||
| Q1 24 | — | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $172.1M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $61.0M | $164.2M |
| 总资产 | $258.3M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CHRSRVSB
| Q4 25 | $172.1M | $28.6M | ||
| Q3 25 | $191.7M | $32.8M | ||
| Q2 25 | $237.6M | $34.2M | ||
| Q1 25 | — | $29.4M | ||
| Q4 24 | — | $25.3M | ||
| Q3 24 | — | $31.0M | ||
| Q2 24 | $159.2M | $27.8M | ||
| Q1 24 | — | $23.6M |
股东权益CHRSRVSB
| Q4 25 | $61.0M | $164.2M | ||
| Q3 25 | $87.8M | $163.5M | ||
| Q2 25 | $119.8M | $162.0M | ||
| Q1 25 | — | $160.0M | ||
| Q4 24 | — | $158.3M | ||
| Q3 24 | — | $160.8M | ||
| Q2 24 | $-84.1M | $155.9M | ||
| Q1 24 | — | $155.6M |
总资产CHRSRVSB
| Q4 25 | $258.3M | $1.5B | ||
| Q3 25 | $516.5M | $1.5B | ||
| Q2 25 | $439.5M | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | $674.9M | $1.5B | ||
| Q1 24 | — | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.7M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-736.0K |
| 自由现金流率自由现金流/营收 | — | -5.2% |
| 资本支出强度资本支出/营收 | — | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | — | $20.4M |
8季度趋势，按日历期对齐
经营现金流CHRSRVSB
| Q4 25 | $-19.7M | $-506.0K | ||
| Q3 25 | $-46.3M | $16.8M | ||
| Q2 25 | $-46.6M | $-697.0K | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $764.0K | ||
| Q2 24 | $59.7M | $5.4M | ||
| Q1 24 | — | $12.8M |
自由现金流CHRSRVSB
| Q4 25 | — | $-736.0K | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $-773.0K | ||
| Q1 25 | — | $5.6M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $5.3M | ||
| Q1 24 | — | $7.1M |
自由现金流率CHRSRVSB
| Q4 25 | — | -5.2% | ||
| Q3 25 | — | 120.1% | ||
| Q2 25 | — | -5.8% | ||
| Q1 25 | — | 43.1% | ||
| Q4 24 | — | 15.0% | ||
| Q3 24 | — | -11.3% | ||
| Q2 24 | — | 43.7% | ||
| Q1 24 | — | 79.0% |
资本支出强度CHRSRVSB
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 21.0% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 17.3% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 62.0% |
现金转化率CHRSRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | -0.16× | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
RVSB
暂无分部数据
